Results 161 to 170 of about 309,141 (294)

Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer. [PDF]

Cancer Immunol Immunother
Huang YH, Wu SY, Lee CT, Chung BS, Lin PC, Chan RH, Chen PC, Lin BW, Shen MR, Chen SH, Yeh YM.   +10 more
europepmc   +1 more source

Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation

Advanced Science, EarlyView.
This study identifies FXYD1 as an epigenetically silenced tumor suppressor in breast cancer. DNA methylation turns off the gene FXYD1 in breast cancer, and low levels predict worse outcomes. Restoring FXYD1 limits breast cancer cells proliferation and metastasis. In the nucleus, FXYD1 recruits the E3 ligase MAEA to K63‐ubiquitinate DDX5 for proteasomal
Ping Wen, Fanli Qu, Long Wang, Qing Shao, Sisi Li, Yang Qin, Dongping Jiang, Senmiao Zhang, Jiangdong Sui, Guanwen Wang, Ningning Zhang, Xiaohua Zeng   +11 more
wiley   +1 more source

Microbiota-metabolite signatures in metastatic colorectal cancer: Promise, pitfalls, and the path forward. [PDF]

World J Gastrointest Oncol
Zhang TT, Yao J, Zhang HM.
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

PRELID1 and VDAC3 Coordinate a Senescence‐Like State in Germinal Center B Cells to Promote IL‐7–Driven Antitumor Immunity in Colorectal Cancer

Advanced Science, EarlyView.
Colorectal cancer is characterized by an immunosuppressive microenvironment that limits immunotherapy efficacy. We identify a senescence‐like state in germinal center B cells driven by the PRELID1–VDAC3 axis, which promotes IL‐7 secretion, alleviates CD8+ T‐cell exhaustion, and enhances antitumor immunity. Targeting this pathway improves responsiveness
Yuhan Liao, Huimeng Xu, Xinghua Zhuo, Shupeng Hu, Lanhui Huang, Zhe Hao, Jianxiong Chen, Yulu Wang, Jun Zhou   +8 more
wiley   +1 more source

Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer. [PDF]

Medicina (Kaunas)
Duygulu ME, Karaman E, Karakullukçu S, Aydın Mungan S.   +3 more
europepmc   +1 more source

Tumor‐Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis

Advanced Science, EarlyView.
Gastric cancer‐derived exosomal TAGLN2 is identified as a key mediator of vascular reprogramming, with significantly elevated levels detected in patient serum. Independent of canonical SEMA4D signaling, it nucleates a cytoplasmic TAGLN2/NRP1/SEMA4D ternary complex that dually activates YAP, promoting angiogenesis, vascular dysfunction, and metastasis ...
Shuqi Yu, Jiajia Zhuo, Xiaoquan Hong, Shihao Rao, Yafang Ye, Dandan Kang, Huifang Peng, Huiqin Zhuo   +7 more
wiley   +1 more source

Prognostic Role of Endocan and Platelet-Derived Growth Factor Isoforms in Metastatic Colorectal Cancer. [PDF]

Int J Mol Sci
Yıldız A, Ahmed MA, Azizy A, Çokgezer S, Ulufer B, Soydinç HO, Karabulut S, Taştekin D, Şakar B, Ak N.   +9 more
europepmc   +1 more source

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer? [PDF]

Cancers (Basel)
Specchia M, Drittone D, Mazzotti E, Mazzuca F.   +3 more
europepmc   +1 more source